RxDoctor Payments Data

Arthur Tarricone, DPM

Podiatrist · San Antonio, TXNPI 1316566540

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (46.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Kerecis Limited at 45.7% of the total. 2025 is the largest year on record at $2,304, 3.9 times the $597 reported in 2022.

$3,714in general payments, 2019–2025

Across 23 payments — averaging $161.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kerecis Limited$2K
  • Paragon 28, Inc.$523
  • Polynovo North America LLC$393
  • Shockwave Medical, Inc$326
  • Stryker$160
  • Johnson & Johnson$147
  • plus $466 from 7 others
$157,108in research payments, 2019–2025

Across 1 payment — averaging $157,108 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Solventum Corporation$157K

What the payments were for

  • Speaking & faculty fees$1,60043%
  • Travel & lodging$38510%
  • Food & beverage$1,72847%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,714 in reported general payments places this provider in the 60th percentile of 470 podiatrist providers in Texas.

See all podiatrist providers in Texas

Medicare billing

Part B allowed, 2024
$9,301
Medicare patients
66
Services billed
133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ciclopirox47$1,733
Ammonium Lactate17$484
Ketoconazole17$297
Clotrimazole13$122

Paid to pharmacies, not to this prescriber.

Other podiatrist in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →